- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Intensity Therapeutics Inc (INTS)
Intensity Therapeutics Inc stock price live, this page displays NASDAQ INTS stock exchange data. View the INTS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Intensity Therapeutics Inc real time stock price chart below.
What Is the Intensity Therapeutics Inc Stock Price Today?
The Intensity Therapeutics Inc stock price today is 4,100.
What Is the Stock Symbol for Intensity Therapeutics Inc?
The stock symbol for Intensity Therapeutics Inc is "INTS."
What Stock Exchange Does Intensity Therapeutics Inc Trade On?
Intensity Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Intensity Therapeutics Inc a Good Stock to Buy?
Determining whether Intensity Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INTS quote. (ISIN: US45828J2024)
What Is the Intensity Therapeutics Inc Stock Price Today?
The Intensity Therapeutics Inc stock price today is 4,100.
What Is the Stock Symbol for Intensity Therapeutics Inc?
The stock symbol for Intensity Therapeutics Inc is "INTS."
What Stock Exchange Does Intensity Therapeutics Inc Trade On?
Intensity Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Intensity Therapeutics Inc a Good Stock to Buy?
Determining whether Intensity Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INTS quote. (ISIN: US45828J2024)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.990
4.110
52 wk Range
0.407
43.500
INTS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.9904.110
52 wk Range
0.40743.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INTS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
19.333
Upside
+371.54%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
Form 4 Intensity Therapeutics Inc For: 1 July- Investing.com
Form 8K Intensity Therapeutics Inc For: 11 August- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 19.333
(+371.54% Upside)
Intensity Therapeutics Inc Earnings Call Summary for Q2/2026
- Intensity Therapeutics posted Q2 2026 adjusted loss of $1.11/share, missing analyst estimates of $0.87/share by 27.6%.
- Shares declined 4.62% to $4.092 in premarket trading; stock remains volatile with beta of 3.03 and market cap of $11.6M.
- Company faces ongoing cash burn concerns requiring additional funding to advance clinical cancer trial programs.
- Analyst price targets range $12-$32; stock trades below 52-week high of $43.5 but maintains strong current ratio of 4.86.
Last Updated: 2026/08/11, 14:58
Read Full TranscriptEarnings
Latest Release
Aug 11, 2026
EPS / Forecast
-1,11 / -0,87
Revenue / Forecast
-- / --
Compare INTS to Peers and Sector
Metrics to compare | INTS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINTSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | −2.4x | −0.4x | |
PEG Ratio | −0.02 | −0.03 | 0.00 | |
Price/Book | 1.4x | 3.5x | 2.6x | |
Price / LTM Sales | - | 17.4x | 3.1x | |
Upside (Analyst Target) | 337.5% | 76.7% | 49.6% | |
Fair Value Upside | Unlock | 3.2% | 7.1% | Unlock |
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Intensity Therapeutics (INTS) Stock Price Today?
The Intensity Therapeutics stock price today is 4,100 USD.
What Stock Exchange Does Intensity Therapeutics Trade On?
Intensity Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Intensity Therapeutics?
The stock symbol for Intensity Therapeutics is "INTS."
What Is the Intensity Therapeutics Market Cap?
As of today, Intensity Therapeutics market cap is 13,060M USD.
What Is Intensity Therapeutics's Earnings Per Share (TTM)?
The Intensity Therapeutics EPS (TTM) is -4,799.
When Is the Next Intensity Therapeutics Earnings Date?
Intensity Therapeutics will release its next earnings report on Nov 17, 2026.
From a Technical Analysis Perspective, Is INTS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Intensity Therapeutics Stock Split?
Intensity Therapeutics has split 2 times.
What is the current trading status of Intensity Therapeutics (INTS)?
As of Sep 04, 2026, Intensity Therapeutics (INTS) is trading at a price of 4,100 USD, with a previous close of 4,000 USD. The stock has fluctuated within a day range of 3,990 USD to 4,110 USD, while its 52-week range spans from 0,407 USD to 43,500 USD.
What Is Intensity Therapeutics (INTS) Price Target According to Analysts?
The average 12-month price target for Intensity Therapeutics is 19,333 USD, with a high estimate of 32 USD and a low estimate of 7 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +371,54% Upside potential.
What Is the INTS Premarket Price?
INTS's last pre-market stock price is 3,970 USD. The pre-market share volume is 963,000, and the stock has decreased by -0,030, or -0,750%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.